{"entity":{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","aka":["RAMP203"],"tldr":"A phase 1/2 trial of Sotorasib in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., active and no longer recruiting.","summary":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients is a phase 1/2 interventional study registered as NCT05074810 by Verastem, Inc., with 153 participants planned, started 2022-04-12 and due to reach its primary completion in 2026-06. Interventions recorded: avutometinib and sotorasib, avutometinib and sotorasib and defactinib. Conditions listed: Non Small Cell Lung Cancer, KRAS Activating Mutation. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05074810","url":"https://clinicaltrials.gov/study/NCT05074810"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","kras-g12c-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["sotorasib"],"companies":["verastem"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05074810","phase":"1/2","setting":"A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Verastem, Inc.","participation":[{"nct":"NCT05074810","source":"https://clinicaltrials.gov/study/NCT05074810","fetchedAt":"2026-10-07T16:53:34.066Z","studySha256":"94f6374a9aa3bd329323f76a012a5f3029f99f0d33e534ad682db275afa4ca70","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-12","leadSponsor":"Verastem, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":153,"enrolmentType":"ESTIMATED","siteCount":35,"recruitingSiteCount":0,"countries":["Belgium","France","Netherlands","Spain","United Kingdom","United States"]}],"started":"2022-04-12","startedType":"actual","enrolled":153,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05074810/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"company":[{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}]}}